{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:04:03Z","timestamp":1789459443029,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03697-y","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:16:22Z","timestamp":1789456582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient and Healthcare Professional Attitudes and Trial Experiences with a Subcutaneous Long-Acting Injectable Olanzapine (TV-44749) for Schizophrenia Treatment"],"prefix":"10.1007","author":[{"given":"Andrew J.","family":"Cutler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6840-1535","authenticated-orcid":false,"given":"Mark","family":"Suett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6405-3952","authenticated-orcid":false,"given":"Kelli R.","family":"Franzenburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7342-1461","authenticated-orcid":false,"given":"Jane Lazar","family":"Tucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1567-3281","authenticated-orcid":false,"given":"Elizabeth","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7273-1202","authenticated-orcid":false,"given":"Sangtaeck","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"issue":"9","key":"3697_CR1","first-page":"638","volume":"39","author":"KR Patel","year":"2014","unstructured":"Patel KR, Cherian J, Gohil K, Atkinson D. Schizophrenia: overview and treatment options. P T. 2014;39(9):638\u201345.","journal-title":"P T"},{"issue":"6","key":"3697_CR2","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1093\/schbul\/sby058","volume":"44","author":"FJ Charlson","year":"2018","unstructured":"Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 2018;44(6):1195\u2013203.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3697_CR3","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41398-021-01671-6","volume":"11","author":"W Bai","year":"2021","unstructured":"Bai W, Liu ZH, Jiang YY, Zhang QE, Rao WW, Cheung T, et al. Worldwide prevalence of suicidal ideation and suicide plan among people with schizophrenia: a meta-analysis and systematic review of epidemiological surveys. Transl Psychiatry. 2021;11(1):552.","journal-title":"Transl Psychiatry"},{"issue":"3","key":"3697_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/jamapsychiatry.2017.4437","volume":"75","author":"GE Simon","year":"2018","unstructured":"Simon GE, Stewart C, Yarborough BJ, Lynch F, Coleman KJ, Beck A, et al. Mortality rates after the first diagnosis of psychotic disorder in adolescents and young adults. JAMA Psychiat. 2018;75(3):254\u201360.","journal-title":"JAMA Psychiat"},{"issue":"2","key":"3697_CR5","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1002\/wps.20994","volume":"21","author":"CU Correll","year":"2022","unstructured":"Correll CU, Solmi M, Croatto G, Schneider LK, Rohani-Montez SC, Fairley L, et al. Mortality in people with schizophrenia: a systematic review and meta-analysis of relative risk and aggravating or attenuating factors. World Psychiatry. 2022;21(2):248\u201371.","journal-title":"World Psychiatry"},{"key":"3697_CR6","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2147\/PPA.S53795","volume":"7","author":"G Kaplan","year":"2013","unstructured":"Kaplan G, Casoy J, Zummo J. Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adher. 2013;7:1171\u201380.","journal-title":"Patient Prefer Adher"},{"issue":"1\u20133","key":"3697_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.schres.2011.08.024","volume":"133","author":"R Boden","year":"2011","unstructured":"Boden R, Brandt L, Kieler H, Andersen M, Reutfors J. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res. 2011;133(1\u20133):36\u201341.","journal-title":"Schizophr Res"},{"issue":"5","key":"3697_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40263-021-00815-y","volume":"35","author":"D Lin","year":"2021","unstructured":"Lin D, Thompson-Leduc P, Ghelerter I, Nguyen H, Lafeuille MH, Benson C, et al. Real-world evidence of the clinical and economic impact of long-acting injectable versus oral antipsychotics among patients with schizophrenia in the United States: a systematic review and meta-analysis. CNS Drugs. 2021;35(5):469\u201381.","journal-title":"CNS Drugs"},{"issue":"1","key":"3697_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40801-019-00172-9","volume":"7","author":"C Patel","year":"2020","unstructured":"Patel C, Emond B, Lafeuille MH, Cote-Sergent A, Lefebvre P, Tandon N, et al. Real-world analysis of switching patients with schizophrenia from oral risperidone or oral paliperidone to once-monthly paliperidone palmitate. Drugs Real World Outcomes. 2020;7(1):19\u201329.","journal-title":"Drugs Real World Outcomes"},{"key":"3697_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/1471-244X-13-261","volume":"13","author":"S Potkin","year":"2013","unstructured":"Potkin S, Bera R, Zubek D, Lau G. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia. BMC Psychiatry. 2013;13:261.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"3697_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41537-023-00334-3","volume":"9","author":"CU Correll","year":"2023","unstructured":"Correll CU, Benson C, Emond B, Patel C, Lafeuille MH, Lin D, et al. Comparison of clinical outcomes in patients with schizophrenia following different long-acting injectable event-driven initiation strategies. Schizophrenia (Heidelb). 2023;9(1):9.","journal-title":"Schizophrenia (Heidelb)"},{"issue":"1","key":"3697_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1080\/13696998.2022.2084234","volume":"25","author":"C Patel","year":"2022","unstructured":"Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, et al. National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States. J Med Econ. 2022;25(1):792\u2013807.","journal-title":"J Med Econ"},{"issue":"4","key":"3697_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/appy.12393","volume":"12","author":"CT Tang","year":"2020","unstructured":"Tang CT, Chua EC, Chew QH, He YL, Si TM, Chiu HF, et al. Patterns of long acting injectable antipsychotic use and associated clinical factors in schizophrenia among 15 Asian countries and region. Asia Pac Psychiatry. 2020;12(4):e12393.","journal-title":"Asia Pac Psychiatry"},{"key":"3697_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.770276","volume":"9","author":"J Zhu","year":"2021","unstructured":"Zhu J, Chen Y, Lu W, Huang Q, Li B, Xu Y, et al. Attitudes and willingness to accept long-acting injections for patients with schizophrenia in Beijing: a cross-sectional investigation based on samples from the communities. Front Public Health. 2021;9:770276.","journal-title":"Front Public Health"},{"issue":"5","key":"3697_CR15","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","volume":"22","author":"S Heres","year":"2007","unstructured":"Heres S, Schmitz FS, Leucht S, Pajonk FG. The attitude of patients towards antipsychotic depot treatment. Int Clin Psychopharmacol. 2007;22(5):275\u201382.","journal-title":"Int Clin Psychopharmacol"},{"key":"3697_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/NDT.S326299","volume":"18","author":"L Citrome","year":"2022","unstructured":"Citrome L, Belcher E, Stacy S, Suett M, Mychaskiw M, Salinas GD. Management of schizophrenia with long-acting injectable antipsychotic medications: an assessment of the educational needs of clinicians. Neuropsychiatr Dis Treat. 2022;18:111\u201323.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3697_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-340","volume":"13","author":"PM Llorca","year":"2013","unstructured":"Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.","journal-title":"BMC Psychiatry"},{"issue":"suppl 3","key":"3697_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4088\/JCP.15032su1","volume":"77","author":"CU Correll","year":"2016","unstructured":"Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, et al. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 2016;77(suppl 3):1\u201324.","journal-title":"J Clin Psychiatry"},{"key":"3697_CR19","first-page":"1097","volume":"16","author":"P Kolli","year":"2023","unstructured":"Kolli P, Kelley G, Rosales M, Faden J, Serdenes R. Olanzapine pharmacokinetics: a clinical review of current insights and remaining questions. Pharmgenom Pers Med. 2023;16:1097\u2013108.","journal-title":"Pharmgenom Pers Med"},{"key":"3697_CR20","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.2147\/NDT.S209284","volume":"15","author":"L Citrome","year":"2019","unstructured":"Citrome L, McEvoy JP, Todtenkopf MS, McDonnell D, Weiden PJ. A commentary on the efficacy of olanzapine for the treatment of schizophrenia: the past, present, and future. Neuropsychiatr Dis Treat. 2019;15:2559\u201369.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3697_CR21","unstructured":"CHEPLAPHARM Registration GmbH. ZYPREXA (olanzapine) tablets; ZYPREXA ZYDIS (olanzapine) orally disintegrating tablets; ZYPREXA IntraMuscular injection: prescribing information. L\u00f6rrach, Germany; 2026."},{"key":"3697_CR22","unstructured":"CHEPLAPHARM Registration GmbH. ZYPREXA RELPREVV (olanzapine) for extended-release injectable suspension: prescribing information. L\u00f6rrach, Germany; 2026."},{"key":"3697_CR23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-244X-10-45","volume":"10","author":"DP McDonnell","year":"2010","unstructured":"McDonnell DP, Detke HC, Bergstrom RF, Kothare P, Johnson J, Stickelmeyer M, et al. Post-injection delirium\/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism. BMC Psychiatry. 2010;10:45.","journal-title":"BMC Psychiatry"},{"issue":"12","key":"3697_CR24","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/S2215-0366(23)00288-2","volume":"10","author":"JM Kane","year":"2023","unstructured":"Kane JM, Harary E, Eshet R, Tohami O, Weiser M, Leucht S, et al. Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. Lancet Psychiatry. 2023;10(12):934\u201343.","journal-title":"Lancet Psychiatry"},{"issue":"8","key":"3697_CR25","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40263-024-01102-2","volume":"38","author":"JM Kane","year":"2024","unstructured":"Kane JM, Eshet R, Harary E, Tohami O, Elgart A, Knebel H, et al. A long-term safety and tolerability study of TV-46000 for subcutaneous use in patients with schizophrenia: a phase 3, randomized, double-blinded clinical trial. CNS Drugs. 2024;38(8):625\u201336.","journal-title":"CNS Drugs"},{"key":"3697_CR26","unstructured":"Correll CU, Shulman K, Bar-Nur T, Budovsky RG, Sharon N, Jehassi A, et al. Long-term effectiveness with subcutaneous long-acting injectable olanzapine (TV-44749) in adults with schizophrenia: results from up to 48 weeks open-label treatment in the phase 3 SOLARIS trial. In: Poster presented at: 38th Annual Psych Congress; San Diego, CA. Schizophrenia2025. Poster 96."},{"key":"3697_CR27","unstructured":"Correll CU, Shulman K, Bar-Nur T, Budovsky RG, Sharon N, Jehassi A, et al. Long-term safety of subcutaneous long-acting injectable olanzapine (TV-44749) in schizophrenia: results from the phase 3 SOLARIS trial. In: Poster presented at: 38th Annual Psych Congress; San Diego, CA. Schizophrenia2025. Poster 97."},{"issue":"5","key":"3697_CR28","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1007\/s12325-023-02455-8","volume":"40","author":"DG Robinson","year":"2023","unstructured":"Robinson DG, Suett M, Wilhelm A, Chaijale N, Franzenburg KR, Gandhi S, et al. Patient and healthcare professional preferences for characteristics of long-acting injectable antipsychotic agents for the treatment of schizophrenia. Adv Ther. 2023;40(5):2249\u201364.","journal-title":"Adv Ther"},{"issue":"1","key":"3697_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/schizbullopen\/sgaf032","volume":"7","author":"KR Franzenburg","year":"2026","unstructured":"Franzenburg KR, Hansen R, Suett M, Yaari A, Peyser Levin A, Sergerie M, et al. Attitudes driving regional differences in long-acting injectable antipsychotic utilization for schizophrenia among healthcare professionals, patients, and caregivers (ADVANCE): results from a multinational survey study. Schizophr Bull Open. 2026;7(1):sgaf032. https:\/\/doi.org\/10.1093\/schizbullopen\/sgaf032","journal-title":"Schizophr Bull Open"},{"key":"3697_CR30","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2147\/PPA.S187120","volume":"13","author":"DL Gandell","year":"2019","unstructured":"Gandell DL, Bienen EJ, Gudeman J. Mode of injection and treatment adherence: results of a survey characterizing the perspectives of health care providers and US women 18\u201345 years old. Patient Prefer Adher. 2019;13:351\u201361.","journal-title":"Patient Prefer Adher"},{"issue":"4","key":"3697_CR31","doi-asserted-by":"publisher","first-page":"232","DOI":"10.9740\/mhc.2022.08.232","volume":"12","author":"S Schwartz","year":"2022","unstructured":"Schwartz S, Carilli C, Mian T, Ruekert L, Kumar A. Attitudes and perceptions about the use of long-acting injectable antipsychotics among behavioral health practitioners. Ment Health Clin. 2022;12(4):232\u201340.","journal-title":"Ment Health Clin"},{"issue":"1","key":"3697_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12888-025-06565-1","volume":"25","author":"D Velligan","year":"2025","unstructured":"Velligan D, Salinas GD, Belcher E, Franzenburg KR, Suett M, Thompson S, et al. Clinician differences in attitudes and perceptions on the use of long-acting injectable antipsychotic agents in treating patients with schizophrenia: results from the US DECIDE survey. BMC Psychiatry. 2025;25(1):232.","journal-title":"BMC Psychiatry"},{"issue":"S1","key":"3697_CR33","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1017\/S1092852925100400","volume":"30","author":"L Citrome","year":"2025","unstructured":"Citrome L. Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide. CNS Spectr. 2025;30(S1):S16\u201329.","journal-title":"CNS Spectr"},{"issue":"4","key":"3697_CR34","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1192\/bjpo.bp.116.004382","volume":"3","author":"KJ Meyers","year":"2017","unstructured":"Meyers KJ, Upadhyaya HP, Landry JL, Chhabra-Khanna R, Falk DM, Seetharama Rao B, et al. Postinjection delirium\/sedation syndrome in patients with schizophrenia receiving olanzapine long-acting injection: results from a large observational study. BJPsych Open. 2017;3(4):186\u201392.","journal-title":"BJPsych Open"},{"issue":"5","key":"3697_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1192\/pb.bp.116.055483","volume":"41","author":"L Cahling","year":"2017","unstructured":"Cahling L, Berntsson A, Broms G, Ohrmalm L. Perceptions and knowledge of antipsychotics among mental health professionals and patients. BJPsych Bull. 2017;41(5):254\u20139.","journal-title":"BJPsych Bull"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03697-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03697-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T07:16:25Z","timestamp":1789456585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03697-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":35,"alternative-id":["3697"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03697-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Andrew J. Cutler received research funding from Teva; received consulting fees and travel support from, and participated on an advisory board with, 4M Therapeutics, AbbVie, Actinogen, Alfasigma, Alkermes, Anavex, Autobahn, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Collegium, Corium, Delpor, Intra-Cellular, Johnson & Johnson, Jazz, Knight, LivoNova, Lundbeck, Luye, MapLight, Mentavi, Neumora, Neurocrine, Noven, Otsuka, PaxMedica, Relmada, Sage, Supernus, Teva, Thynk, Tris, Vanda, and VistaGen; received honoraria from AbbVie, Alfasigma, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Collegium, Corium, Intra-Cellular, Johnson & Johnson, Lundbeck, Neurocrine, Noven, Otsuka, Supernus, Teva, Tris, and Vanda; participated on a data safety monitoring board with COMPASS Pathways; and is a stockholder of 4M Therapeutics. Alma Gonzalez, Mark Suett, Kelli R. Franzenburg, and Sangtaeck Lim are stockholders and employees of Teva. Ken Shulman is a stockholder and former employee of Teva. Jane Lazar Tucker and Elizabeth Costa are employees of IQVIA, which received funding from Teva.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The survey was reviewed and approved by the sponsor, Teva Branded Pharmaceutical Products R&D LLC. Materials including the study protocol, survey forms, and consent forms were reviewed and approved by an independent Institutional Review Board (IRB) (The Western IRB-Copernicus Group IRB ID: 20232842). All respondents provided consent via an online informed consent form and were free to decline participation without providing a reason at any time. Respondents received an honorarium payment for completing the survey. The study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}